Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Michael G. McCusker"'
Publikováno v:
ESMO Open, Vol 4, Iss Suppl 2 (2019)
Externí odkaz:
https://doaj.org/article/0923421442fd4966954901f951a7d6a6
Publikováno v:
ESMO Open, Vol 4, Iss Suppl 2 (2019)
Externí odkaz:
https://doaj.org/article/4de43ee759c246048ab798c7c662d9e5
Autor:
Michael G. McCusker, Ranee Mehra, Sania Amr, Rodney J. Taylor, Kevin J. Cullen, Olga G. Goloubeva
Publikováno v:
Head & Neck. 44:749-759
The best chemoradiation regimen to treat locally and regionally advanced head and neck squamous cell carcinoma (HNSCC) is yet to be established.We compared overall survival (OS) and adverse events following chemoradiation regimens (high-dose [HDC] or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d411548dcec6f3681de89ade5ab7e2eb
https://doi.org/10.1002/hed.26965
https://doi.org/10.1002/hed.26965
Autor:
Ana Rita Lopes, Michael G. McCusker, Christian Rolfo, Andrew Y. Li, Katherine A. Scilla, Alessandro Russo, Ranee Mehra, Jeffrey Myles Kroopnick
Publikováno v:
Transl Lung Cancer Res
Immune-mediated endocrinopathies are among the most frequent immune-related adverse events (irAEs) with immune checkpoint inhibitors (ICIs) targeting programmed death-ligand 1 (PD-L1)/PD-1. However, the development of auto-immune diabetes is an uncom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cdbee6d74cad55087a2b404506f6aaaa
https://doi.org/10.21037/tlcr-20-408
https://doi.org/10.21037/tlcr-20-408
Publikováno v:
OncoTargets and Therapy. 13:3047-3059
Relapsed and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) is a heterogeneous disease previously associated with poor prognosis and limited treatment options until the advent and implementation of immune checkpoint inhibitors (ICIs)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9607c5ebdd440f5dd4f798875eb18ac3
https://doi.org/10.2147/ott.s196252
https://doi.org/10.2147/ott.s196252
Autor:
Andrew Y. Li, Allen P. Burke, Michael G. McCusker, Gabriela Sanchez-Petitto, Naomi Hardy, Ashraf Z. Badros
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:e392-e394
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ddb0fb997f31229acc485add4c6d5f2
https://doi.org/10.1016/j.clml.2020.03.015
https://doi.org/10.1016/j.clml.2020.03.015
Autor:
Jeremiah O, Pasion, Linda H, Song, Michael G, McCusker, Leeann, Shimer, Alexis, Bryant, Heather L, McGann, Magali J, Fontaine
Publikováno v:
Annals of clinical and laboratory science. 51(2)
Managing a platelet blood product inventory in a hospital-based transfusion service (TS) is challenging. Thus, to optimize platelet inventory availability and to prevent excess outdating, most tertiary care center-based TSs do not require ABO-identic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::24f6e2c383f8a9a3296e4a2047f160b7
https://pubmed.ncbi.nlm.nih.gov/33941569
https://pubmed.ncbi.nlm.nih.gov/33941569
Publikováno v:
Expert opinion on emerging drugs. 25(4)
Introduction: The benefits of immune checkpoint inhibitors (ICIs) in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) have been demonstrated through multiple studies ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3411ac1487900292d2c19559f6eb999
https://pubmed.ncbi.nlm.nih.gov/33196319
https://pubmed.ncbi.nlm.nih.gov/33196319
Autor:
Alessandro, Russo, Michael G, McCusker, Katherine A, Scilla, Katherine E, Arensmeyer, Ranee, Mehra, Vincenzo, Adamo, Christian, Rolfo
Publikováno v:
Advances in experimental medicine and biology. 1244
Over the last decade, we have witnessed a paradigm shift in cancer treatment, with the advent of novel therapeutic approaches that target or manipulate the immune system, also known as immunotherapy. Blocking immune checkpoints has emerged as an effe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::caab410645f1e86ef00c90620847a83f
https://pubmed.ncbi.nlm.nih.gov/32301011
https://pubmed.ncbi.nlm.nih.gov/32301011
Autor:
Alessandro Russo, Michael G. McCusker, Ana Rita Lopes, Giuseppina Rosaria Rita Ricciardi, Sandra Gimenez Garrigues, Ranee Mehra, Christian Rolfo, Katherine A. Scilla, Katherine E Arensmeyer
Publikováno v:
Current oncology reports. 22(5)
Over the last two decades, the identification of targetable oncogene drivers has revolutionized the therapeutic landscape of non-small cell lung cancer (NSCLC). The extraordinary progresses made in molecular biology prompted the identification of sev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14cf94e72829633a984b948b21c2068a
https://pubmed.ncbi.nlm.nih.gov/32296961
https://pubmed.ncbi.nlm.nih.gov/32296961